Pharmaceuticals firm Zydus Lifesciences announced Q4FY23 & FY23 results: Q4FY23: Revenue from Operations at Rs 50,106 million, up 32% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 3,541 million (7.1% of revenues). EBITDA for the quarter was Rs 12,556 million, up 75% YoY. EBITDA margin for the quarter was 25.1% against 18.9% in Q4 FY22. Adjusted for one-time COVID related inventory provision of Rs 1,435 million made in Q4 FY22, EBITDA grew by 46% YoY. Net Profit adjusted for the exceptional expense in Q4 FY23 was Rs 8,979 million, up 126% YoY. Excluding the exceptional expense, one-time COVID related inventory provision and profit/ (loss) of discontinued operations, net profit was up by 71% YoY. Capex (organic) for the quarter was Rs 2,040 million. FY23: Revenue from Operations at Rs 1,72,374 million, up 14% over last year. Research & Development (R&D;) investments for the year stood at Rs 12,363 million (7.2% of revenues). Reported EBITDA for the year was Rs 38,599 million, up 16% YoY. EBITDA margin for the year was 22.4% against 22.1% last year. Adjusted for COVID related inventory provision made in FY23 and FY22, EBITDA margin for the year was 23.1% against 23.3% last year. Net Profit adjusted for the exceptional items and profit/ (loss) of discontinued operations, was Rs 25,691 million, up 19% YoY. Capex (organic) for the year was Rs 9,579 million. Net Debt to Equity ratio as on 31st March, 2023 was -0.03x while Net Debt to EBITDA stood at -0.14x at the end of March, 2023. Net Cash (negative Net Debt) as on March 31, 2023 was Rs 5,461 million. We are delighted to have maintained growth momentum across all our key businesses throughout the year, ending the fiscal year on a strong note with steady improvement in profitability and balance sheet health. We are well poised to maintain growth momentum, with India geography likely to hold double-digit growth, the US business continuing to leverage our robust product pipeline and agile supply chain and scale-up of our emerging market business. We are committed to upholding high quality management standards and working constantly to enhance them. We are advancing our innovation efforts with an aim to serve the patients’ needs across markets and improving their health outcomes. Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited Result PDF